^
    Back
    Association details:
    Biomarker:HER-2 mutation + TP53 wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug:Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Exp Hematol Oncol
    Title:

    Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

    Published date:
    06/09/2023
    Excerpt:
    Patients with TP53 wild type, ctDNA nonshedding, or clearance showed superior efficacy of pyrotinib in patients with HER2-mutated advanced NSCLC...
    DOI:
    https://doi.org/10.1186/s40164-023-00417-y
    Trial ID:
    NCT02834936; NCT02535507